Gary Gordon Acquires 10,000 Shares of TriSalus Life Sciences (NASDAQ:TLSI) Stock

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Director Gary Gordon purchased 10,000 shares of TriSalus Life Sciences stock in a transaction that occurred on Friday, May 15th. The shares were bought at an average price of $2.46 per share, for a total transaction of $24,600.00. Following the completion of the transaction, the director owned 72,510 shares in the company, valued at $178,374.60. The trade was a 16.00% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

TriSalus Life Sciences Trading Up 13.1%

TLSI traded up $0.35 on Monday, hitting $3.03. 774,431 shares of the company were exchanged, compared to its average volume of 276,402. The firm has a fifty day simple moving average of $4.18 and a two-hundred day simple moving average of $5.13. The company has a debt-to-equity ratio of 2.58, a quick ratio of 5.46 and a current ratio of 5.78. TriSalus Life Sciences, Inc. has a 12 month low of $2.20 and a 12 month high of $7.95. The stock has a market capitalization of $185.77 million, a PE ratio of -2.15 and a beta of 0.56.

TriSalus Life Sciences (NASDAQ:TLSI) last posted its quarterly earnings results on Thursday, March 5th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.01. The company had revenue of $13.21 million for the quarter, compared to the consensus estimate of $13.20 million. Sell-side analysts expect that TriSalus Life Sciences, Inc. will post -0.45 earnings per share for the current year.

Wall Street Analyst Weigh In

TLSI has been the topic of several recent research reports. Canaccord Genuity Group reduced their price target on TriSalus Life Sciences from $12.00 to $7.00 and set a “buy” rating on the stock in a research report on Friday, March 6th. Weiss Ratings lowered TriSalus Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday. Wall Street Zen upgraded TriSalus Life Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, March 7th. Finally, Lake Street Capital reduced their price target on TriSalus Life Sciences from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, May 13th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $7.50.

Institutional Investors Weigh In On TriSalus Life Sciences

Large investors have recently made changes to their positions in the business. JPMorgan Chase & Co. grew its position in shares of TriSalus Life Sciences by 35,804.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company’s stock worth $41,000 after buying an additional 7,519 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of TriSalus Life Sciences in the 2nd quarter worth approximately $47,000. Invesco Ltd. bought a new stake in shares of TriSalus Life Sciences in the 4th quarter worth approximately $72,000. Abel Hall LLC bought a new stake in shares of TriSalus Life Sciences in the 4th quarter worth approximately $73,000. Finally, HighMark Wealth Management LLC bought a new stake in shares of TriSalus Life Sciences in the 4th quarter worth approximately $75,000. 2.58% of the stock is currently owned by institutional investors.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.